Back
Regeneron Pharmaceuticals Quote, Financials, Valuation and Earnings
Buy
65
REGN
Regeneron Pharmaceuticals
Last Price:
982.60
Seasonality Move:
8.1%
7 Day Trial
ALL ACCESS PASS
$
7
Regeneron Pharmaceuticals Price Quote
$982.60
+0.31 (+1.51%)
(Updated: May 18, 2024 at 5:52 AM ET)
Regeneron Pharmaceuticals Key Stats
Buy
65
Regeneron Pharmaceuticals (REGN)
is a Buy
Day range:
$966.00 - $982.77
52-week range:
$684.81 - $998.33
Dividend yield:
0%
P/E ratio:
28.25
P/S ratio:
8.55
P/B ratio:
4.01%
Volume:
386.5K
Avg. volume:
470.6K
1-year change:
31.04%
Market cap:
$108.2B
Revenue:
$13.1B
EPS:
$33.85
How Much Does Regeneron Pharmaceuticals Make?
-
How Much Are Regeneron Pharmaceuticals's Sales Annually?
REGN Revenues are $13.1B -
How Much Profit Does Regeneron Pharmaceuticals's Make A Year?
REGN net income is $4B
Is Regeneron Pharmaceuticals Growing As A Company?
-
What Is Regeneron Pharmaceuticals's Growth Rate Quarterly?
Quarterly YoY revenue growth is -0.01% -
What Is Regeneron Pharmaceuticals's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is -0.13%
Regeneron Pharmaceuticals Stock Price Performance
-
Did Regeneron Pharmaceuticals Stock Go Up Last Month?
Regeneron Pharmaceuticals share price went up by 9% last month -
Did REGN's Share Price Rise Over The Last Year?
REGN share price rose by 31.04% over the past 1 year
What Is Regeneron Pharmaceuticals 52-Week High & Low?
-
What Is Regeneron Pharmaceuticals’s 52-Week High Share Price?
Regeneron Pharmaceuticals has traded as high as $998.33 over the past 52 weeks -
What Is Regeneron Pharmaceuticals’s 52-Week Low Share Price?
Regeneron Pharmaceuticals has traded as low as $684.81 over the past 52 weeks
Regeneron Pharmaceuticals Price To Free Cash Flow
-
Is Regeneron Pharmaceuticals Stock Overvalued?
Regeneron Pharmaceuticals is trading at a price to free cash flow ratio of 28.50 -
Is Regeneron Pharmaceuticals Stock Undervalued?
Regeneron Pharmaceuticals EV to Free Cash Flow ratio is 25.37 -
What Is Regeneron Pharmaceuticals’s Price Earnings Growth Ratio?
REGN PEG ratio is 0.00 -
Is Regeneron Pharmaceuticals Trading At A Premium To Earnings?
Regeneron Pharmaceuticals EV to EBIT ratio is 24.24
Is It Risky To Buy Regeneron Pharmaceuticals?
-
How Much Debt Does Regeneron Pharmaceuticals Have?
Total long term debt quarterly is $2B -
How Much Cash Does Regeneron Pharmaceuticals Have?
Cash and short term investments quarterly total is $10.5B -
What Is Regeneron Pharmaceuticals’s Book Value Per Share?
Book value per share is 244.96
Is Regeneron Pharmaceuticals Cash Flow Positive?
-
What Is REGN Cash Flow From Operations?
Cash flow from operations (TTM) is $4.7B -
What Is Regeneron Pharmaceuticals’s Cash Flow From Financing?
Cash flow from financing (TTM) is -$1.4B -
What Is Regeneron Pharmaceuticals’s Cash Flow From Investing?
Cash flow from investing (TTM) is -$4.6B
Regeneron Pharmaceuticals Return On Invested Capital
-
Is Management Doing A Good Job?
REGN return on invested capital is 14.26% -
What Is Regeneron Pharmaceuticals Return On Assets?
ROA measures how assets are converting to revenues and is 12.03% -
What Is REGN Return On Equity?
ROE is a measure of profitability and is 15.38%
Regeneron Pharmaceuticals Earnings Date & Stock Price
-
What Is Regeneron Pharmaceuticals's Stock Price Today?
A single share of REGN can be purchased today for 982.29 -
What Is Regeneron Pharmaceuticals’s Stock Symbol?
Regeneron Pharmaceuticals trades on the S&P500 under the ticker symbol: REGN -
When Is Regeneron Pharmaceuticals’s Next Earnings Date?
The next quarterly earnings date for Regeneron Pharmaceuticals is scheduled on August 2, 2024 -
When Is REGN's next ex-dividend date?
Regeneron Pharmaceuticals's next ex-dividend date is May 18, 2024 -
How To Buy Regeneron Pharmaceuticals Stock?
You can buy Regeneron Pharmaceuticals shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Regeneron Pharmaceuticals Competitors
-
Who Are Regeneron Pharmaceuticals's Competitors?
Below is a list of companies who compete with Regeneron Pharmaceuticals or are related in some way:
Regeneron Pharmaceuticals Dividend Yield
Data Unavailable
Regeneron Pharmaceuticals Analyst Estimates
| YoY Growth | Past Surprise | |
|---|---|---|
| EPS: | -12.55% | -5.41% |
| Revenue: | -0.54% | -2.35% |
Analyst Recommendations
| Buy Recommendations: | 11 |
|---|---|
| Hold Recommendations: | 6 |
| Sell Recommendations: | 0 |
| Price Target: | 1,041.52 |
| Upside from Last Price: | 6.03% |